The Centers for Medicare & Medicaid Services (CMS) TPT program facilitates Medicare patient access to new and innovative device technologies that have shown substantial clinical improvement over standard of care.
This important program allows for adequate payment of innovative products while CMS collects the data necessary to incorporate the cost of these technologies into permanent ambulatory payment classification (APC) outpatient payment rates.
As of January 1, 2020, the TriNav Infusion System is approved for TPT reimbursement.
After review of the TriNav application, supporting clinical data and favorable comments from the stakeholders, CMS determined that TriNav met the narrow program eligibility criteria, including demonstration of substantial clinical improvement compared to existing devices.1